Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ron Bentsur
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Beta
- -0.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 26.62
Financials
Net Income
$-30.07MEBITDA
$-31.05MFree Cash Flow
$-25.28MEPS (diluted)
$-1.02Shares Outstanding (diluted)
29.47M+131.7%Operating Expenses
$31.05MCash & Debt
$140.71MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-26.44M | $-1.32 |
| 2024 | $0.00 | $-19.00M | $-1.11 |
| 2023 | $0.00 | $-22.26M | $-1.43 |
| 2022 | $0.00 | $-19.09M | $-1.51 |
| 2021 | $0.00 | $-12.89M | $-1.09 |
| 2020 | $0.00 | $-10.0K | $-0.00 |
Valuation
NVCThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (7)
- Newsfool.com·5h ago·Positive
Nuvectis: 3 Key Takeaways for Long-Term Investors Nuvectis ended the third quarter with $140 million in cash. NXP-100 demonstrated an average hemoglobin increase of 5 grams per deciliter.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·18d ago·Negative
Nuvectis Pharma Q3 Earnings Call Highlights Nuvectis Pharma NASDAQ: NVCT said its third quarter marked a strategic shift into late-stage development following a licensing agreement with Haisco for ex-China rights to two drug candidates: ciprocopan, also known as NXP100, and NXP200.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. The Company's lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor (CFBi) for once-daily oral administration, was approved in China in July 2026 for the treatment of patients with Paroxysmal Noctur
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progre…
View source ↗ - Newsglobenewswire.com·44d ago·Neutral
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Nuvectis Pharma To Participate in Upcoming Investor Conferences Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fir…
View source ↗
Earnings
Wed, Feb 10(in 3 months)
Consensus estimate $-0.37 per share
Typical surprise -19.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-1.02 vs $-0.24miss
- Tue, Aug 4$-0.30 vs $-0.26miss
- Tue, May 5$-0.26 vs $-0.30beat
- Wed, Feb 11$-0.31 vs $-0.26miss
- Tue, Nov 4$-0.44 vs $-0.24miss
- Tue, Aug 5$-0.30 vs $-0.25miss
Estimates and results for NVCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NVCT officers and directors.
- Bought
- $7.9m
- Sold
- $22k
72 trades
1 trade
- Mosseri Marlio Charlesbought
- Bentsur Ronbought
- Bentsur Ronbought
- Sanchez Juanbought
- Kaplan Matthew L.bought
- Mosseri Marlio Charlesbought
- Mosseri Marlio Charlesbought
- Mosseri Marlio Charlesbought
27 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NVCT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
